What is Synexis?
Founded in 2008, Synexis LLC is a prominent player in the microbial reduction sector, distinguished by its patented Dry Hydrogen Peroxide (DHP) technology. This unique system continuously disperses DHP in occupied indoor spaces, offering round-the-clock microbial reduction. Synexis BioDefense systems are recognized by the U.S. Environmental Protection Agency (EPA) as antimicrobial devices, with production occurring in an EPA-registered facility. The company's focus on regulated, effective microbial control solutions positions it as a key innovator in public health and safety.
How much funding has Synexis raised?
Synexis has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in Synexis
PPP
Public-Private Partnership
What's next for Synexis?
The substantial enterprise-level backing Synexis has received, particularly the recent strategic investment, signals a phase of accelerated growth and market expansion. This capital infusion is likely to fuel further research and development of its patented DHP technology, enhance manufacturing capabilities, and broaden its market reach within sectors prioritizing advanced microbial control. The company's trajectory suggests a strategic focus on solidifying its position as a leader in regulated antimicrobial solutions, potentially exploring new applications and partnerships to leverage its unique technological advantage.
See full Synexis company page
